Pharma Pulse 2/13/25: The Transformative Power of Data Analytics, Growing Popularity of Non-hormonal Menopause Therapies & more

The Transformative Power of Data Analytics in Clinical Trials

Leveraging and benchmarking insights to boost efficiency and optimization.

The Growing Popularity of Non-hormonal Menopause Therapy

Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.

DOGE Cuts Pose Risk to Largest Government Contractors

The Trump administration’s moves to trim government spending pose a short-term “understated risk” for companies all across the corporate credit market, according to a Barclays Plc analysis.

SmithRx Unveils 2024 Growth Momentum, Reducing Pharmacy Benefit Costs by an Average of 30%

SmithRx published its newest report, “SmithRx: Milestones and Momentum in 2024,” which unveiled the company’s significant growth, cost savings, customer satisfaction, and market traction from 2024. The momentum SmithRx achieved over the past year is a direct result of the company’s commitment to challenging legacy models, driving innovation, and delivering value beyond dollars and cents – reflecting how SmithRx is building a new pharmacy benefits system that works for employers and employees alike.

Robert Minicucci (He/Him) on LinkedIn

The Impact of #SocialMedia Distrust on #Pharmaceutical #Marketing

(If it sounds too go to be true, it most likely is.)

https://lnkd.in/eKmnrkHC via Pharmaceutical Executive

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs